Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC33330 Cynaropicrin

    菜蓟苦素

    A sesquiterpene lactone
  3. GC33312 ML311 An Mcl-1 inhibitor
  4. GC33309 ML132 (NCGC 00185682)

    NCGC-00183434

    ML132 (NCGC 00185682) (NCGC-00183434) 是一种选择性 caspase 1 抑制剂,IC50 为 34.9 nM。

  5. GC33295 MIK665 (S-64315)

    S-64315

    An Mcl-1 inhibitor
  6. GC33291 Tubulin inhibitor 1 Tubulininhibitor1是tubulin抑制剂,靶作用于秋水仙素结合位点,抑制微管蛋白聚集。Tubulininhibitor1具有抗肿瘤活性,能够导致细胞G2/M期有丝分裂停滞,诱导细胞凋亡。
  7. GC33283 AZD-5991 Racemate AZD5991 is a macrocyclic MCL-1 inhibitor with sub-nanomolar affinity for MCL-1 (Ki = 0.13 nM). The binding affinity of AZD5991 is about 25-fold lower for mouse Mcl-1 vs. human Mcl-1 but only four-fold lower for rat Mcl-1.
  8. GC33255 AZD4320 AZD4320是BH-3的新型类似物,有效的BCL2/BCLxL的双重抑制剂。AZD4320对于KPUM-MS3,KPUM-UH1,和STR-428细胞系的IC50分别为26nM,17nM,和170nM。
  9. GC33247 AZD-5991 An Mcl-1 inhibitor
  10. GC33239 AZD-5991 S-enantiomer AZD-5991S-enantiomer是AZD-5991的低活性S型对映体。AZD-5991S-enantiomer是一种Mcl-1抑制剂,FRET实验检测的IC50为6.3μM,SPR实验检测的Kd为0.98μM。
  11. GC33218 CA-5f CA-5f 是一种有效的晚期巨自噬/自噬抑制剂,通过抑制自噬体-溶酶体融合。 CA-5f 增加 LC3B-II(一种监测自噬的标志物)和 SQSTM1 蛋白,并且还增加 ROS 的产生。抗肿瘤活性。
  12. GC33200 Target Protein-binding moiety 13

    PROTAC FKBP12-binding moiety 1

    Target Protein-binding moiety 13 (PROTAC FKBP12-binding moiety 1) 是 FKBP (SLF) 的合成配体。目标蛋白结合部分 13(PROTAC FKBP12 结合部分 1)可用于 PROTAC 的合成。
  13. GC33189 SAR125844 SAR125844 is a potent intravenously active and highly selective Met (c-Met) kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively).
  14. GC33167 Rhosin An inhibitor of the Rho-GEF protein-protein interaction
  15. GC33156 Ecteinascidin 770 (Ecteinascidine 770)

    Ecteinascidine 770; Et-770

    Ecteinascidin 770 (Ecteinascidin 770) (ET-770) 是一种 1,2,3,4-四氢异喹啉生物碱,具有有效的抗癌活性;抑制 U373MG 细胞,IC50 为 4.83 nM。
  16. GC33155 Tubulysin A (TubA)

    N-(2-氨基-2-氧代乙基)-N-(羧甲基)甘氨酸,TubA

    Tubulysin A (TubA)(TubA) 是一种粘细菌产品,可在许多体外试验中用作抗血管生成剂;抗微管、抗有丝分裂、凋亡诱导剂、抗癌、抗血管生成和抗增殖。
  17. GC33143 Podocarpusflavone A

    竹柏双黄酮 A;罗汉松双黄酮A

    A biflavone with diverse biological activities

  18. GC33133 SPD304 A small-molecule inhibitor of TNFα activity
  19. GC33097 GDP366 GDP366是survivin和Op18的双重抑制剂,抑制癌细胞生长,诱导细胞衰老和有丝分裂突变。
  20. GC33092 Hesperin

    6-MSITC

    An isothiocyanate with diverse biological activities
  21. GC33074 SSE15206 SSE15206是一种微管(microtubule)聚合抑制剂,其在HCT116细胞SRB增殖实验中的GI50值为197nM。
  22. GC33052 VU0661013 VU661013 is a novel, potent, selective MCL1 inhibitor with Ki of 97 ± 30 pM of human MCL-1 in a TR-FRET assay. However, VU661013 does not significantly inhibit BCL-xL or BCL-2 with Ki > 40 μM or = 0.73 μM. VU661013 de-stabilizes BIM/MCL-1 association, leads to apoptosis in AML.
  23. GC33043 EL-102 EL102是HIF1α的抑制剂,能够抑制微管蛋白聚合和减少它的稳定性。
  24. GC33035 Mcl1-IN-2

    7-[(2-吡啶基氨基)-2-噻吩基甲基]-8-喹啉醇

    Mcl1-IN-2 是骨髓细胞因子 1 (Mcl-1) 的抑制剂。 Mcl1-IN-2 是一种非竞争性的德里 metallo-β-lactamase (NDM-1) 抑制剂。

  25. GC33029 Forodesine (BCX-1777 freebase)

    呋咯地辛; BCX-1777; Immucillin-H

    A nucleoside analog and PNP inhibitor
  26. GC33002 PBOX 6 PBOX6是一种pyrrolo-1,5-benzoxazepine(PBOX)化合物,可作为微管解聚剂和促凋亡剂起作用。
  27. GC32998 Ginsenoside Rh4

    人参皂苷RH4

    Ginsenoside Rh4 is an important active ingredient of traditional Chinese medicine ginseng, which has been shown to inhibit Wnt/β-Catenin, JAK2/STAT3, TGF-β/Smad2/3 and other signaling pathways.
  28. GC32997 Cinchonine ((8R,9S)-Cinchonine)

    辛可宁; (8R,9S)-Cinchonine; LA40221

    Cinchonine (LA40221) is an alkaloid and a stereoisomer and pseudo-enantiomer of cinchonidine.
  29. GC32981 A-385358 A-385358是Bcl-XL的一个选择性抑制剂,对于Bcl-XL和Bcl-2的Ki值分别为0.80和67nM。
  30. GC32973 SID 3712249 (MiR-544 Inhibitor 1)

    MiR-544 Inhibitor 1

    An inhibitor of miR-544 biogenesis
  31. GC32947 S55746 (BLC201)

    BCL201

    S55746 (S 055746,BCL201) is a novel, orally active BCL-2 specific inhibitor (Ki = 1.3 nM) with poor affinity for BCL-XL and no significant binding to MCL-1, BFL-1 (BCL2A1/A1). The selectivity of S55746 for BCL-2 versus BCL-XL ranges from ~70 to 400 folds.
  32. GC32946 PK11007 PK11000 stabilizes the DBD of both WT and mutant p53 proteins by covalent cysteine modification without compromising DNA binding and effective in inducing cell death.
  33. GC32929 MIR96-IN-1 MIR96-IN-1选择性抑制微小RNA-96的生物合成,上调蛋白靶点(FOXO1)且诱导癌细胞凋亡。
  34. GC32919 Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride)

    4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride

    An activator of p53
  35. GC32911 CTX1

    CTX1是一种新型小分子p53激活剂。

  36. GC32901 ROC-325 An autophagy inhibitor
  37. GC32895 Maytansinol (Ansamitocin P-0)

    美登醇,Ansamitocin P-0

    An ansa macrolide
  38. GC32881 Milademetan (DS-3032)

    DS-3032

    Milademetan (DS-3032) (DS-3032) 是一种特异性的、具有口服活性的 MDM2 抑制剂,用于研究急性髓性白血病 (AML) 或实体瘤。 Milademetan (DS-3032) (DS-3032) 诱导 G1 细胞周期停滞、衰老和凋亡。
  39. GC32860 RIP2 kinase inhibitor 2 RIP2kinaseinhibitor2是一种受体相互作用蛋白-2(RIP2)激酶抑制剂,详细信息请参考专利WO/2014043437A1中的化合物example9。
  40. GC32853 PD0166285

    6-(2,6-二氯苯基)-2-[[4-[2-(二乙基氨基)乙氧基]苯基]氨基]-8-甲基吡啶并[2,3-D]嘧啶-7(8H)-酮

    PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.
  41. GC32841 Catechin ((+)-Catechin)

    儿茶素; (+)-Catechin; Cianidanol; Catechuic acid

    (+)-Catechin (Cianidanol, Catechinic acid, Catechuic acid) is an antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.
  42. GC32807 HJC0152 hydrochloride

    2-(2-氨基乙氧基)-5-氯-N-(2-氯-4-硝基苯基)苯甲酰胺盐酸盐

    An orally bioavailable inhibitor of STAT3
  43. GC32803 ASTX660

    Tolinapant

    A non-peptidomimetic inhibitor of IAP protein-peptide interactions
  44. GC32781 CUDC-427 (GDC-0917)

    GDC-0917

    CUDC-427 (GDC-0917) 是一种有效的第二代泛选择性 IAP 拮抗剂,用于治疗各种癌症。
  45. GC32775 RIP2 kinase inhibitor 1 GSK2983559 active metabolite is an active metabolite of GSK2983559, also is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
  46. GC32767 3BDO

    3BDO,MTOR激酶激活剂,自噬抑制剂

    A butyrolactone derivative and autophagy inhibitor
  47. GC32762 Icaritin (Anhydroicaritin)

    去水淫羊藿黄素

    Icaritin (Anhydroicaritin)是从中药淫羊藿中提取的天然黄酮类化合物。Icaritin (Anhydroicaritin)常用于抗癌、骨骼保护、抗炎、神经保护、心血管保护和抗病毒等领域的研究。
  48. GC32753 Taltobulin (HTI-286)

    N,BETA,BETA-三甲基-L-苯基丙氨酰基-N-[(1S,2E)-3-羧基-1-(1-甲基乙基)-2-丁烯基]-N,3-二甲基-L-缬氨酰胺,HTI-286; SPA-110

    An inhibitor of microtubule polymerization
  49. GC32737 TAK-243 (MLN7243)

    MLN7243

    TAK-243 (MLN7243)是一种选择性泛素活化酶(UBA1)抑制剂,IC50值为1nM。
  50. GC32729 Rhosin hydrochloride

    G04

    An inhibitor of the Rho-GEF protein-protein interaction
  51. GC32724 LW6 (HIF-1α inhibitor)

    HIF-1α inhibitor; LW8

    LW6是一种缺氧诱导因子1(hypoxia inducing factor 1, HIF)抑制剂,通过降解HIF-1α有效抑制HIF-1α的积累,但不影响缺氧时HIF- 1a mRNA水平。

Items 1751 to 1800 of 2733 total

per page

Set Descending Direction